CHF283.70
0.56% yesterday
SIX Swiss Exchange, Oct 17, 05:32 pm CET
ISIN
CH0012032048
Symbol
ROG
Index

Roche Target price 2025 - Analyst rating & recommendation

Roche Classifications & Recommendation:

Buy
46%
Hold
31%
Sell
23%

Roche Price Target

Target Price CHF297.84
Price CHF283.70
Potential 4.98%
Number of Estimates 21
21 Analysts have issued a price target Roche 2026 . The average Roche target price is CHF297.84. This is 4.98% higher than the current stock price. The highest price target is CHF459.90 62.11% , the lowest is CHF237.35 16.34% .
A rating was issued by 26 analysts: 12 Analysts recommend Roche to buy, 8 to hold and 6 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Roche stock has an average upside potential 2026 of 4.98% . Most analysts recommend the Roche stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2032


Dec '24 2025
Estimates
Revenue Billion CHF 60.50 63.08
3.03% 4.27%
EBITDA Margin 33.78% 39.77%
5.15% 17.72%
Net Margin 13.68% 25.16%
30.13% 83.89%

20 Analysts have issued a sales forecast Roche 2025 . The average Roche sales estimate is CHF63.1b . This is 2.42% higher than the revenue of the last 12 months(TTM). The highest sales forecast is CHF68.2b 10.74% , the lowest is CHF59.9b 2.80% .

This results in the following potential growth metrics:

Revenue Estimates

2024 CHF60.5b 3.03%
2025 CHF63.1b 4.27%
2026 CHF65.1b 3.28%
2027 CHF67.6b 3.70%
2028 CHF68.8b 1.83%
2029 CHF71.8b 4.36%
2030 CHF76.4b 6.43%
2031 CHF80.5b 5.32%
2032 CHF78.9b 1.89%

18 Analysts have issued an Roche EBITDA forecast 2025. The average Roche EBITDA estimate is CHF25.1b . This is 18.68% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is CHF27.6b 30.44% , the lowest is CHF22.3b 5.51% .

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 CHF20.4b 8.34%
2025 CHF25.1b 22.75%
2026 CHF26.1b 4.02%
2027 CHF27.0b 3.36%
2028 CHF28.9b 7.28%
2029 CHF31.0b 7.31%
2030 CHF32.0b 3.01%
2031 CHF33.4b 4.57%
2032 CHF32.7b 2.33%

EBITDA Margin

2024 33.78% 5.15%
2025 39.77% 17.72%
2026 40.06% 0.73%
2027 39.92% 0.35%
2028 42.06% 5.36%
2029 43.25% 2.83%
2030 41.86% 3.21%
2031 41.57% 0.69%
2032 41.38% 0.46%

21 Roche Analysts have issued a net profit forecast 2025. The average Roche net profit estimate is CHF15.9b . This is 68.31% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is CHF17.9b 89.35% , the lowest is CHF12.9b 37.00% .

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 CHF8.3b 28.01%
2025 CHF15.9b 91.73%
2026 CHF16.7b 5.00%
2027 CHF17.6b 5.89%
2028 CHF19.0b 7.45%
2029 CHF20.5b 8.12%
2030 CHF21.5b 5.09%
2031 CHF22.7b 5.19%
2032 CHF22.7b 0.35%

Net Margin

2024 13.68% 30.13%
2025 25.16% 83.89%
2026 25.58% 1.67%
2027 26.12% 2.11%
2028 27.56% 5.51%
2029 28.55% 3.59%
2030 28.20% 1.23%
2031 28.16% 0.14%
2032 28.80% 2.27%

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032


Dec '24 2025
Estimates
Earnings Per Share CHF 10.32 19.94
27.83% 93.22%
P/E 14.31
EV/Sales 3.94

21 Analysts have issued a Roche forecast for earnings per share. The average Roche EPS is CHF19.94 . This is 69.70% higher than earnings per share in the financial year 2024. The highest EPS forecast is CHF22.43 90.89% , the lowest is CHF16.23 38.13% .

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 CHF10.32 27.83%
2025 CHF19.94 93.22%
2026 CHF20.93 4.96%
2027 CHF22.17 5.92%
2028 CHF23.82 7.44%
2029 CHF25.75 8.10%
2030 CHF27.06 5.09%
2031 CHF28.47 5.21%
2032 CHF28.57 0.35%

P/E ratio

Current 24.28 19.78%
2025 14.31 41.06%
2026 13.63 4.75%
2027 12.87 5.58%
2028 11.98 6.92%
2029 11.08 7.51%
2030 10.54 4.87%
2031 10.02 4.93%
2032 9.99 0.30%

Based on analysts' sales estimates for 2025, the Roche stock is valued at an EV/Sales of 3.94 and an P/S ratio of 3.61 .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 4.04 3.12%
2025 3.94 2.44%
2026 3.82 3.17%
2027 3.68 3.57%
2028 3.61 1.79%
2029 3.46 4.17%
2030 3.25 6.04%
2031 3.09 5.05%
2032 3.15 1.92%

P/S ratio

Current 3.70 1.11%
2025 3.61 2.36%
2026 3.49 3.17%
2027 3.37 3.57%
2028 3.31 1.80%
2029 3.17 4.17%
2030 2.98 6.04%
2031 2.83 5.05%
2032 2.88 1.92%

Current Roche Upgrades & Downgrades

Analyst Rating Action Date
DAY BY DAY
Hold
Buy
Upgrade Sep 08 2025
HSBC GLOBAL INVESTMENT RESEARCH
Hold
Hold
Unchanged Aug 25 2025
TD COWEN
Hold
Hold
Unchanged Aug 12 2025
BERENBERG
Hold
Hold
Unchanged Aug 11 2025
ROTHSCHILD & CO REDBURN
Buy
Buy
Unchanged Aug 04 2025
DZ BANK
Buy
Buy
Unchanged Jul 28 2025
LANDESBANK BADEN-WUERTTEMBERG
Buy
Buy
Unchanged Jul 25 2025
Analyst Rating Date
Upgrade
DAY BY DAY:
Hold
Buy
Sep 08 2025
Unchanged
HSBC GLOBAL INVESTMENT RESEARCH:
Hold
Hold
Aug 25 2025
Unchanged
TD COWEN:
Hold
Hold
Aug 12 2025
Unchanged
BERENBERG:
Hold
Hold
Aug 11 2025
Unchanged
ROTHSCHILD & CO REDBURN:
Buy
Buy
Aug 04 2025
Unchanged
DZ BANK:
Buy
Buy
Jul 28 2025
Unchanged
LANDESBANK BADEN-WUERTTEMBERG:
Buy
Buy
Jul 25 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today